Key statistics
On Tuesday, Rapport Therapeutics Inc (RAPP:NMQ) closed at 28.25, -33.17% below its 52-week high of 42.27, set on Sep 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 27.31 |
|---|---|
| High | 28.99 |
| Low | 26.81 |
| Bid | 25.00 |
| Offer | 38.65 |
| Previous close | 27.28 |
| Average volume | 283.27k |
|---|---|
| Shares outstanding | 47.66m |
| Free float | 45.43m |
| P/E (TTM) | -- |
| Market cap | 1.30bn USD |
| EPS (TTM) | -2.71 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
- Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
- Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
- Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
- Rapport Therapeutics to Participate in Upcoming Investor Conferences
- Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
- Rapport Announces Pricing of Public Offering of Common Stock
- Rapport Announces Proposed Public Offering of Common Stock
- Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
More ▼
